Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

NCT ID: NCT07174336Sponsor: Eli Lilly and CompanyLast updated: 2026-06-04

Summary

The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.

Arms & interventions

  • DrugLY4064809

    Administered orally

  • DrugPlacebo

    Administered orally

  • DrugRibociclib

    Administered orally

  • DrugPalbociclib

    Administered orally

  • DrugAbemaciclib

    Administered orally

  • DrugAnastrozole

    Administered orally

  • DrugLetrozole

    Administered orally

  • DrugExemestane

    Administered orally

  • DrugFulvestrant

    Administered intramuscular

Outcome measures

Primary

  • (Part 1): Overall Response Rate (ORR): Percentage of Participants with Confirmed Complete Response (CR) or Partial Response (PR)

    As determined by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1

    Time frame: Baseline through disease progression or death (Estimated up to 5 years)

  • (Part 2): Progression-Free Survival

    Investigator-assessed

    Time frame: Baseline to objective progression or death due to any cause (Estimated up to 5 years)

Secondary

  • (Part 1): Disease Control Rate (DCR)

    Time frame: Baseline through measured progressive disease (Estimated up to 5 years)

  • (Part 1): Time to Response (TTR)

    Time frame: Baseline until the date that measurement criteria for CR or PR (whichever is first recorded) are first met (Estimated as approximately 5 years)

  • (Parts 1 and 2): Duration of Response (DOR)

    Time frame: Date of CR or PR to date of objective disease progression or death due to any cause (Estimated up to 5 years)

  • (Part 1): PFS

    Time frame: Baseline to objective progression or death due to any cause (Estimated up to 5 years)

  • (Parts 1 and 2): Overall Survival (OS)

    Time frame: Baseline to deaths from any cause (Estimated up to 7 years)

  • (Part 1): Best Overall Response (BOR)

    Time frame: Baseline to disease progression or death from any cause (Estimated up to 5 years)

  • (Parts 1 and 2): Clinical Benefit Rate (CBR): Percentage of Participants with a BOR of CR or PR, or SD Lasting Greater than or Equal to Six Months

    Time frame: Baseline to disease progression or death from any cause (Estimated up to 5 years)

  • (Parts 1 and 2): PK: Average Plasma Concentrations of LY4064809

    Time frame: Baseline to last PK sample collection up to 5 months

  • (Part 2): Progression-Free Survival after Subsequent Line of Treatment (PFS2)

    Time frame: Baseline to disease progression on next line of treatment or death from any cause (Estimated as up to 7 years)

  • (Part 2): Progression-Free Survival (PFS)

    Time frame: Baseline to objective progression or death from any cause (Estimated up to 5 years)

  • (Part 2): Objective Response Rate (ORR)

    Time frame: Baseline to disease progression or death from any cause (Estimated up to 5 years)

  • (Part 2): Time to Chemotherapy (TTC)

    Time frame: Baseline until the start of chemotherapy (Estimated up to 7 years)

  • (Part 2): Chemotherapy-Free Survival

    Time frame: Baseline until the start of chemotherapy or death from any cause (Estimated up to 7 years)

  • (Part 2): Change in Overall Health-related Quality of Life (HRQoL) as measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Subscale

    Time frame: Baseline until disease progression or death (Estimated up to 7 years)

  • (Part 2): Change in Physical Function as measured by the EORTC QLQ-C30 Physical Functioning Subscale

    Time frame: Baseline until disease progression or death (Estimated up to 7 years)

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Are willing to follow contraception requirements. Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * If assigned female at birth, pre-/peri- and postmenopausal status is allowed. Those with pre- or peri-menopausal status at study entry must agree to use ovarian function suppression with any locally approved gonadotropin-releasing hormone (GnRH) agonist. * If assigned male at birth with an estrogen receptor positive (ER+) breast cancer diagnosis, they must agree to use hormone suppression with a GnRH agonist. * Have histologically or cytologically confirmed breast cancer, defined as individuals with * locally advanced breast cancer not amenable to curative therapy (for example, surgery) or metastatic disease, and * hormone receptors (HR)+/human epidermal growth factor receptor 2 (HER2)- or HR+/HER low defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guidelines * HR status: Documented ER+ and/or progesterone receptor-positive (PR+) tumor according to ASCO/CAP Guidelines, defined as greater than or equal to (≥)1 percent (%) of tumor cells stained positive based on the most recent tumor biopsy and assessed locally * HER status: immunohistochemistry score of 1+ or score of 2+ with a negative Fluorescence In Situ Hybridization (FISH) based on local results as defined in the ASCO/CAP Guidelines * Have evidence of an activating PIK3CA mutation, detected in tumor or blood samples using an appropriate assay. * Have measurable disease or non-measurable, evaluable bone disease * Part 1: * Received 0-2 prior systemic treatments for advanced breast cancer not amenable to curative therapy (for example, surgery) or metastatic disease. * Up to 1 of these prior systemic treatments may contain chemotherapy * Part 2: * Received 0 prior systemic treatment for advanced breast cancer not amenable to curative therapy (for example, surgery) or metastatic disease. * Individuals who are eligible are either * Population 1 (P1): Endocrine sensitive * newly diagnosed with advanced breast cancer (de novo) * relapsed with documented evidence of progression greater than (\>)12 months from completion of (neo)adjuvant ET ± cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor, or * Population 2 (P2): Endocrine resistant * relapsed with documented evidence of progression less than or equal to (≤)12 months of completing (neo)adjuvant ET ± CDK4/6 inhibitor. * if a CDK4/6 inhibitor was included as part of neoadjuvant or adjuvant therapy, progression event must be \>12 months since completion of CDK4/6 inhibitor portion of neoadjuvant or adjuvant therapy. Exclusion Criteria: * Have an established diagnosis of Type 1 diabetes mellitus or Type 2 diabetes mellitus with hemoglobin A1c (HbA1c) ≥8%, fasting blood glucose (FBG) ≥140 milligrams per deciliter (mg/dL) (7.7 millimoles per liter \[mmol/L\]), or requiring insulin. * Have inflammatory or metaplastic breast cancer. * History of leptomeningeal disease or carcinomatous meningitis. * Have known and untreated or active central nervous system (CNS) metastases. Exception: Asymptomatic brain or spinal metastases if treated by surgery, surgery plus radiotherapy, or radiotherapy alone with no evidence of radiographic progression or hemorrhage within at least 28 days before randomization and no requirement for anticonvulsants or systemic corticosteroids for at least 28 days before randomization. * Have received treatment with any local or systemic antineoplastic therapy or investigational anticancer agent within 14 days or 4 half-lives, whichever is longer, prior to randomization up to a maximum washout period of 28 days. * Have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dose more than 10 milligrams \[mg\] daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization. * Are pregnant, breastfeeding, or intend to become pregnant during the study or within 6 months of the last dose of study intervention and at least 2 years after the last dose of fulvestrant and/or CDK4/6 inhibitor after the final administration of study treatment.

Study locations (117)

Alaska Oncology and Hematology

Anchorage, Alaska, 99508

Not Yet Recruiting
· Contact
Steven Liu · Principal Investigator

Ironwood Cancer & Research Centers

Chandler, Arizona, 85224

Not Yet Recruiting
Jasleen Khanuja · Principal Investigator

Mayo Clinic in Arizona - Phoenix

Phoenix, Arizona, 85054

Not Yet Recruiting
· Contact
Shakeela Bahadur · Principal Investigator

The University of Arizona Cancer Center - North Campus

Tucson, Arizona, 85719

Not Yet Recruiting
Sima Ehsani · Principal Investigator

Genesis Cancer and Blood Institute

Hot Springs, Arkansas, 71913

Not Yet Recruiting
· Contact
Stephen Divers · Principal Investigator

Highlands Oncology Group

Springdale, Arkansas, 72762

Recruiting
· Contact
Joseph Beck · Principal Investigator

Community Cancer Institute

Clovis, California, 93611

Not Yet Recruiting
Li Ge · Principal Investigator

City of Hope

Duarte, California, 91010

Not Yet Recruiting
Hope Rugo · Principal Investigator

Marin Cancer Care

Greenbrae, California, 94904

Recruiting
Cyrus Mazidi · Principal Investigator

Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine

Irvine, California, 92612

Not Yet Recruiting
· Contact
Ritesh Parajuli · Principal Investigator

City of Hope Orange County Lennar Foundation Cancer Center

Irvine, California, 92618

Not Yet Recruiting
Hope Rugo · Principal Investigator

Moores Cancer Center

La Jolla, California, 92093

Not Yet Recruiting
Xiaojie Zhang · Principal Investigator

USC/Norris Comprehensive Cancer Center

Los Angeles, California, 90033

Not Yet Recruiting
· Contact
Daphne Stewart · Principal Investigator

Hoag Memorial Hospital Presbyterian

Newport Beach, California, 92663

Not Yet Recruiting
Chaitali Nangia · Principal Investigator

Kaiser Permanente Oakland

Oakland, California, 94611

Not Yet Recruiting
· Contact
Jennifer Suga · Principal Investigator

Profound Research LLC

Oceanside, California, 92056

Not Yet Recruiting
Catherine Quinn · Principal Investigator

University of California, Irvine (UCI) Health - UC Irvine Medical Center

Orange, California, 92868

Not Yet Recruiting
· Contact
Ritesh Parajuli · Principal Investigator

Desert Regional Medical Center

Palm Springs, California, 92262

Not Yet Recruiting
· Contact
Kim Phan · Principal Investigator

Stanford Cancer Center

Palo Alto, California, 94304

Not Yet Recruiting
Fauzia Riaz · Principal Investigator

Kaiser Permanente

Roseville, California, 95661

Not Yet Recruiting
Jennifer Suga · Principal Investigator

Kaiser Permanente

San Francisco, California, 94115

Not Yet Recruiting
· Contact
Jennifer Suga · Principal Investigator

UCSF Medical Center at Mission Bay

San Francisco, California, 94158

Suspended

Kaiser Permanente

Santa Clara, California, 95051

Not Yet Recruiting
Jennifer Suga · Principal Investigator

UCLA Hematology/Oncology - Parkside

Santa Monica, California, 90404

Not Yet Recruiting
· Contact
Nicholas McAndrew · Principal Investigator

Providence Medical Foundation

Santa Rosa, California, 95403

Recruiting
Ian Anderson · Principal Investigator

Kaiser Permanente

Vallejo, California, 94589

Not Yet Recruiting
Jennifer Suga · Principal Investigator

Kaiser Permanente Walnut Creek

Walnut Creek, California, 94596

Not Yet Recruiting
· Contact
Jennifer Suga · Principal Investigator

Cancer Centers of Colorado St. Mary's Regional Hospital

Grand Junction, Colorado, 81501

Not Yet Recruiting
· Contact
Alicia Swink · Principal Investigator

Banner MD Anderson Cancer Center at North Colorado Medical Center

Greeley, Colorado, 80631

Not Yet Recruiting
· Contact
Esther Mondo · Principal Investigator

Banner MD Anderson Cancer Center at McKee Medical Center

Loveland, Colorado, 80538

Not Yet Recruiting
· Contact
Esther Mondo · Principal Investigator

MedStar Washington Hospital Center

Washington D.C., District of Columbia, 20010

Not Yet Recruiting
Ami Chitalia · Principal Investigator

AdventHealth Altamonte Springs

Altamonte Springs, Florida, 32701

Not Yet Recruiting
Wassim Mchayleh · Principal Investigator

Clermont Oncology Center

Clermont, Florida, 34711

Recruiting
· Contact
Gopal Kunta · Principal Investigator

Florida Oncology & Hematology

Fort Myers, Florida, 33912

Not Yet Recruiting
· Contact
Venkata Parsa · Principal Investigator

Mayo Clinic in Florida

Jacksonville, Florida, 32224

Not Yet Recruiting
· Contact
Rishitha Bollam · Principal Investigator

University of Miami Hospital and Clinics, Sylvester Cancer Center

Miami, Florida, 33136

Not Yet Recruiting
Frances Valdes · Principal Investigator

Mid Florida Hematology and Oncology Center

Orange City, Florida, 32763

Recruiting
· Contact
Santosh Nair · Principal Investigator

Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center

Tampa, Florida, 33612

Not Yet Recruiting
Aixa Soyano · Principal Investigator

Central Georgia Cancer Care

Macon, Georgia, 31210

Not Yet Recruiting
· Contact
Bradley Sumrall · Principal Investigator

City of Hope National Medical Center, Atlanta Cancer Center

Newnan, Georgia, 30265

Not Yet Recruiting
Sarah Friend · Principal Investigator

Summit Cancer Care, PC

Savannah, Georgia, 31405

Recruiting
· Contact
Alison Spellman · Principal Investigator

Kaiser Permanente Moanalua Medical Center

Honolulu, Hawaii, 96819

Not Yet Recruiting
· Contact
Jennifer Carney · Principal Investigator

City of Hope, Chicago

Chicago, Illinois, 60611

Not Yet Recruiting
Ajaz M. Khan · Principal Investigator

Northwestern Memorial Hospital

Chicago, Illinois, 60611

Not Yet Recruiting
William Gradishar · Principal Investigator

University of Illinois at Chicago

Chicago, Illinois, 60612

Not Yet Recruiting
· Contact
Vijayakrishna Gadi · Principal Investigator

Accellacare of Duly

Lisle, Illinois, 60532

Not Yet Recruiting
Daniel Frank · Principal Investigator

Simmons Cancer Institute at SIU

Springfield, Illinois, 62702

Not Yet Recruiting
· Contact
Krishna Rao · Principal Investigator

Indiana University Health University Hospital

Indianapolis, Indiana, 46202

Recruiting
Tarah Ballinger · Principal Investigator

Deaconess Chancellor Center for Oncology

Newburgh, Indiana, 47630

Not Yet Recruiting
Karim Anwar · Principal Investigator

University of Iowa

Iowa City, Iowa, 52242

Not Yet Recruiting
· Contact
Mark Burkard · Principal Investigator

Saint Elizabeth Medical Center Edgewood

Edgewood, Kentucky, 41017

Not Yet Recruiting
Matthew Kurian · Principal Investigator

Our Lady of the Lake RMC

Baton Rouge, Louisiana, 70808

Not Yet Recruiting
Marshall Stagg · Principal Investigator

New England Cancer Specialists

Westbrook, Maine, 04092

Not Yet Recruiting
Eleni Nackos · Principal Investigator

American Oncology Partners, PA

Bethesda, Maryland, 20817

Not Yet Recruiting
· Contact
Victor Priego · Principal Investigator

James M Stockman Cancer Institute

Frederick, Maryland, 21702

Not Yet Recruiting
Natalia Marina · Principal Investigator

Mass General Cancer Center

Boston, Massachusetts, 02114

Not Yet Recruiting
Dejan Juric · Principal Investigator

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215

Not Yet Recruiting
· Contact
Antonio Giordano · Principal Investigator

Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center

Milford, Massachusetts, 01757

Not Yet Recruiting
· Contact
Natalie Sinclair · Principal Investigator

Dana-Farber/Brigham and Women's Cancer Center - South Shore Hospital

South Weymouth, Massachusetts, 02190

Not Yet Recruiting
James Stoeckle · Principal Investigator

University of Massachusetts Medical School

Worcester, Massachusetts, 01655

Not Yet Recruiting
· Contact
Madhavi Toke · Principal Investigator

Profound Research LLC

Sterling Heights, Michigan, 48314

Not Yet Recruiting
Laura Kohler · Principal Investigator

Mayo Clinic in Rochester, Minnesota

Rochester, Minnesota, 55905

Not Yet Recruiting
· Contact
Matthew Goetz · Principal Investigator

North Mississippi Hematology and Oncology Associates

Tupelo, Mississippi, 38801

Not Yet Recruiting
Rana Usman · Principal Investigator

Saint Luke's Cancer Institute

Kansas City, Missouri, 64111

Not Yet Recruiting
· Contact
Timothy Pluard · Principal Investigator

Oncology Hematology Associates

Springfield, Missouri, 65807

Not Yet Recruiting
· Contact
Viran Holden · Principal Investigator

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, 03756

Not Yet Recruiting
Muhammad Afzal · Principal Investigator

Jefferson Health - Cherry Hill

Cherry Hill, New Jersey, 08002

Recruiting
Steven Manobianco · Principal Investigator

Sidney Kimmel Cancer Center - Washington Township

Sewell, New Jersey, 08080

Recruiting
Steven Manobianco · Principal Investigator

Atlantic Health System Overlook Medical Center

Summit, New Jersey, 07901

Not Yet Recruiting
Bonni Guerin · Principal Investigator

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Not Yet Recruiting
· Contact
Komal Jhaveri · Principal Investigator

Messino Cancer Centers

Asheville, North Carolina, 28806

Not Yet Recruiting
Rachel Raab · Principal Investigator

WakeMed Cancer Care - Waverly Hematology & Medical Oncology

Cary, North Carolina, 27518

Not Yet Recruiting
· Contact
Pallavi Kopparthy · Principal Investigator

University of North Carolina Medical Center

Chapel Hill, North Carolina, 27599

Not Yet Recruiting
· Contact
Elizabeth Dees · Principal Investigator

Carolina Cancer Research Center

Wilson, North Carolina, 27893

Not Yet Recruiting
Keith Lerro · Principal Investigator

Sanford Fargo Medical Center

Fargo, North Dakota, 58102

Not Yet Recruiting
Anu Gaba · Principal Investigator

Cleveland Clinic Akron General

Akron, Ohio, 44302

Not Yet Recruiting
· Contact
Daniel Silbiger · Principal Investigator

Gabrail Cancer Center

Canton, Ohio, 44718

Not Yet Recruiting
· Contact
Nashat Gabrail · Principal Investigator

Fairview Hospital

Cleveland, Ohio, 44111

Not Yet Recruiting
· Contact
Daniel Silbiger · Principal Investigator

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T

Columbus, Ohio, 43210

Not Yet Recruiting
· Contact
Robert Wesolowski · Principal Investigator

Cleveland Clinic - Hillcrest Hospital

Mayfield Heights, Ohio, 44124

Not Yet Recruiting
· Contact
Daniel Silbiger · Principal Investigator

Good Samaritan Regional Medical Center

Corvallis, Oregon, 97330

Recruiting
John Strother · Principal Investigator

Oncology Associates of Oregon

Eugene, Oregon, 97401

Recruiting
Miho Dougherty · Principal Investigator

Oregon Health and Science University

Portland, Oregon, 97239

Not Yet Recruiting
· Contact
Annie Hung · Principal Investigator

St. Luke's University Health Network

Bethlehem, Pennsylvania, 18015

Not Yet Recruiting
Maria Hafez · Principal Investigator

Lancaster General Hospital - Ann B Barshinger Cancer Institute

Lancaster, Pennsylvania, 17601

Not Yet Recruiting
Amy Clark · Principal Investigator

University of Pennsylvania Hospital

Philadelphia, Pennsylvania, 19104

Not Yet Recruiting
Amy Clark · Principal Investigator

Thomas Jefferson University - Clinical Research Institute

Philadelphia, Pennsylvania, 19107

Recruiting
Steven Manobianco · Principal Investigator

Jefferson Hospital Northeast

Philadelphia, Pennsylvania, 19114

Recruiting
Steven Manobianco · Principal Investigator

Asplundh Cancer Pavilion

Willow Grove, Pennsylvania, 19090

Recruiting
Steven Manobianco · Principal Investigator

Medical University of South Carolina

Charleston, South Carolina, 29425

Not Yet Recruiting
· Contact
Abirami Sivapiragasam · Principal Investigator

Sarah Cannon Research Institute SCRI

Nashville, Tennessee, 37203

Recruiting
SMO Sarah Cannon Research Inst. · Principal Investigator

Nashville General Hospital

Nashville, Tennessee, 37208

Not Yet Recruiting
· Contact
Robin Jacob · Principal Investigator

Hendrick Medical Center

Abilene, Texas, 79601

Not Yet Recruiting
· Contact
Jose Velasco Di Domenico · Principal Investigator

World Research Link

Baytown, Texas, 77521

Recruiting
· Contact
Amir Rasheed · Principal Investigator

Parkland Health and Hospital System

Dallas, Texas, 75235

Not Yet Recruiting
· Contact
Nisha Unni · Principal Investigator

USO - Texas Oncology

Dallas, Texas, 75246

Recruiting
Joyce O'Shaughnessy · Principal Investigator

UT Southwestern Medical Center

Dallas, Texas, 75390

Recruiting
· Contact
Nisha Unni · Principal Investigator

Texas Oncology - West Texas

El Paso, Texas, 79902

Recruiting
Ines Sanchez · Principal Investigator

The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030-4009

Not Yet Recruiting
· Contact
Senthil Damodaran · Principal Investigator

Houston Methodist Hospital

Houston, Texas, 77030

Not Yet Recruiting
Hanh Mai · Principal Investigator

Oncology Consultants P.A.

Houston, Texas, 77030

Recruiting
· Contact
Ricardo Alvarez · Principal Investigator

Nova Oncology

McAllen, Texas, 78504

Recruiting
· Contact
Raghad Muhsin Abdul Karim, MD · Principal Investigator

Texas Oncology - San Antonio Medical Center

San Antonio, Texas, 78240

Recruiting
Emmalind Aponte · Principal Investigator

US Oncology Research Network

The Woodlands, Texas, 77380

Recruiting
SMO Sarah Cannon Research Inst. · Principal Investigator

Tranquility Research

Webster, Texas, 77598

Not Yet Recruiting
John Knecht · Principal Investigator

Utah Cancer Specialists

Salt Lake City, Utah, 84106

Not Yet Recruiting
Stephan Kendall · Principal Investigator

The University of Vermont Medical Center Inc.

Burlington, Vermont, 05405

Not Yet Recruiting
Peter Kaufman · Principal Investigator

Virginia Cancer Specialists

Fairfax, Virginia, 22031

Not Yet Recruiting
Shruti Tiwari · Principal Investigator

Swedish Cancer Institute - Edmonds

Edmonds, Washington, 98026

Not Yet Recruiting
Michaela Tsai · Principal Investigator

Providence Regional Cancer Partnership

Everett, Washington, 98201

Not Yet Recruiting
Xiaowen Wang · Principal Investigator

UW Medicine Valley Medical Center

Renton, Washington, 98055

Not Yet Recruiting
· Contact
Navanshu Arora · Principal Investigator

Swedish Medical Center

Seattle, Washington, 98104

Not Yet Recruiting
Michaela Tsai · Principal Investigator

Deaconess Hospital

Spokane, Washington, 99204

Not Yet Recruiting
Blair Irwin · Principal Investigator

Cancer Care Northwest - Vercler

Spokane Valley, Washington, 99216

Not Yet Recruiting
Saritha Thumma · Principal Investigator

MultiCare Health System

Tacoma, Washington, 98405

Not Yet Recruiting
Blair Irwin · Principal Investigator

North Star Lodge

Yakima, Washington, 98902

Not Yet Recruiting
Blair Irwin · Principal Investigator

ThedaCare Physicians - Appleton North

Appleton, Wisconsin, 54911

Not Yet Recruiting
· Contact
Shannon Schmidt · Principal Investigator